Falconer, assuming all 7 million sufferers of AD in the EU were cleared to take 2-73 how many, percentage wise, do you think will be taking 2-73? Thanks in advance.
I’m in that ballpark as well Falconer. My simple math is once were approved for Alzheimer’s and becomes a revenue generating biotech company, our market cap should be $10 billion or app $130/share. Throw in all of the other goodness we have in our pipeline and the share price is substantially higher. Take care my friend
Market Data 
Markets 
